To the Editor In a randomized clinical trial, Sridhar et al1 compared the efficacy and safety of nab-paclitaxel vs paclitaxel in platinum-refractory metastatic urothelial cancer. The results failed to demonstrate that nab-paclitaxel was superior to paclitaxel regarding progression-free survival (PFS). However, in the abstract, they suggested that taxanes remain a reasonable option in the platinum-refractory settings, based on comparison with previous reports. We have some concerns about the presentation and interpretation of the results in this study.